Compare Amphastar Pharmaceuticals Inc (AMPH) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Keysight Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Keysight Technologies Inc trades at $325.49 (market cap $55.04B). The key difference: Keysight Technologies Inc is far larger — about 66.6× Amphastar Pharmaceuticals Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | KEYS | |
|---|---|---|
Market Cap | $826.08M | $55.04B |
Sector | Health | Technology |
52-Week High | $30.81 | $373.34 |
52-Week Low | $16.87 | $158.51 |
Enterprise Value | $1.22B | $55.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
KEYS trades at $322.05, down 0.04% on the day, with a bearish technical signal despite strong fundamentals. The company reported revenue of $5.38B in 2025 with net income of $850M, and has beaten EPS estimates for three consecutive quarters. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Outlook remains positive with 75% analyst buy ratings and a $390.30 consensus price target, implying 21% upside. Key risks include high valuation multiples and volatile cash flows from significant investing activities. Earnings growth driven by technology demand presents the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
